SEC Form 4 · accession 0001209191-15-015645
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Curtis Ruegg
Officer — EVP, Technical Operations
Period of report
Feb 17, 2015
Accepted (ET)
Feb 18, 2015 · 7:53 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Feb 17, 2015 | M | 170 | $2.55 | A | 19,507 | D | |
| Common Stock | Feb 17, 2015 | M | 830 | $6.60 | A | 20,337 | D | |
| Common Stock | Feb 17, 2015 | S | 170 | $16.80 | D | 20,167 | D | |
| Common Stock | Feb 17, 2015 | S | 830 | $16.80 | D | 19,337 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $2.55 | Feb 17, 2015 | M | 170 | D | — | Apr 29, 2018 | Common Stock | 170 | 0 | D |
| Stock Option (Right to Buy)F3 | $6.60 | Feb 17, 2015 | M | 830 | D | — | May 15, 2016 | Common Stock | 830 | 3,503 | D |
Explanation of responses
- F1The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on August 15, 2014.
- F2The Option is fully vested as of January 1, 2012.
- F3The Option is fully vested as of May 16, 2010.